January 14, 2016 |
Horizon Pharma Completes Acquisition of Crealta Holdings LLC |
December 11, 2015 |
Horizon Pharma plc to Acquire Crealta Holdings LLC |
January 10, 2014 |
Crealta Completes Acquisition of Savient's Assets |
January 8, 2013 |
Krystexxa® Receives Marketing Approval in EU |
October 19, 2012 |
Savient Receives Positive Opinion for KRYSTEXXA Approval in EU |
June 11, 2012 |
Mountain View Pharmaceuticals Announces Receipt of a European Patent on a Long-Acting Drug for MS |
March 14, 2012 |
Mountain View Pharmaceuticals Announces Receipt of a U.S. Patent
on Next-Generation PEGylation Technology (PharmaPEG)
|
November 30, 2010 |
Savient Announces Price and First Shipment of KRYSTEXXA |
November 2, 2010 |
MVP receives US grant for research on PharmaPEG |
September 14, 2010 |
FDA Approves KRYSTEXXA for Chronic Refractory Gout |
March 30, 2010 |
Savient Announces PDUFA Date of 09-14-10 |
March 15, 2010 |
Savient Resubmits Biologics License Application for KRYSTEXXA |
January 8, 2010 |
Savient Update on KRYSTEXXA BLA Filing |
September 16. 2009 |
Savient provides update on FDA meeting |
September 8, 2009 |
Savient press release re ACR Abstracts |
August 2, 2009 |
Savient Receives Complete Response from FDA |
June 16, 2009 |
FDA Arthritis Advisory Committee Recommends Approval of Pegloticase |
May 29, 2009 |
Savient to Present Multiple Abstracts at 2009 EULAR Congress |
January 28, 2009 |
Savient Announces FDA Advisory Panel |
December 29, 2008 |
FDA Grants Priority Review to Pegloticase BLA Filing |
October 31, 2008 |
Savient Submits Biologics License Application |
October 27, 2008 |
Savient press release on ACR 10-27-08 |
September 22, 2008 |
Savient to Present Abstracts Related to Puricase® at ACR Meeting in October 2008 |
May 7, 2008 |
Savient Reports Favorable Interim Data from Uricase® Open Label Extension Study |
April 21, 2008 |
Savient Provides Update on Puricase®
BLA |
February 4, 2008 |
Savient Reports Additional Positive Phase 3 Results for Puricase® |
December 13, 2007 |
Savient Press Release - Successful Phase 3 Trials of Puricase® |
October 16, 2007 |
Savient Completes Puricase® Phase 3 Study |
March 6, 2007 |
Savient Completes Enrollment for Puricase® Phase 3 Study |
August 4, 2006 |
Savient Completes Rosemont Sale |
June 14, 2006 |
Savient Initiates Patient Dosing for Puricase® Phase 3 Study |
May 3, 2006 |
Savient Receives FDA Final Approval for Puricase® |
March 21, 2006 |
Savient and FDA Agree on Phase 3 Protocol SPA Puricase® (PEG-uricase) on Track to Enter
Phase 3 |
November 14, 2005 |
Savient's Puricase® (PEG-uricase) Substantially Reduces and Sustains Lower Plasma Urate Levels in Patients with Treatment Resistant Gout |
July 28, 2005 |
Savient Pharmaceuticals Meets with FDA for End-of-Phase 2 Review of Puricase® |
June 29, 2005 |
Mountain View Pharmaceuticals Grants Worldwide License for a Long-Acting Protein |
May 12, 2005 |
Savient
Reports Positive Top-Line Results for Phase 2 Trial |
May 4, 2005 |
Mountain View Pharmaceuticals Elects Raymond J. Land to Its Board of Directors |
January 19, 2005 |
Mountain View Pharmaceuticals Grants Worldwide License for Long-Acting Multiple Sclerosis Drug |
January 10, 2005 |
Savient Pharmaceuticals, Inc. Completes Patient Dosing in Phase II Clinical Trial of Puricase for Severe Gout |
July 7, 2003 |
Savient
Pharmaceuticals, Inc. Successfully Completes Phase I Clinical Study of Puricase® for Severe Gout |
August 17, 1998 |
Bio-Technology General Acquires Rights to Technology for Important New Drug, PEG-Uricase, from Duke University and Mountain View Pharmaceuticals, Inc. |